Peer-influenced content. Sources you trust. No registration required. This is HCN.
Pharmacy Times
This updated indication now allows the use of upadacitinib prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable and who have received at least 1 approved systemic therapy.
Clinical Pharmacology October 14th 2025
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS